Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 1
3(75.0%)
N/A
1(25.0%)
4Total
Phase 1(3)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT00835328Phase 1Terminated

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

Role: lead

NCT00897676Phase 1Completed

Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity

Role: lead

NCT00571324Phase 1Completed

Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism

Role: lead

NCT01162499Not ApplicableCompleted

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

Role: lead

All 4 trials loaded